This checklist must be submitted with the Pharmacy Benefit Manager Application.

These standards are summaries only. Review of the entire statute may be necessary. Complete the far-right column to direct reviewers to the page of your submitted documents that demonstrates compliance with the described standard.

FILER: PLEA	SE TYPE INFORMATION I	N THE AREA DIRECTLY BELOV	N.	
Company na				
rederal ID N	iumber:			
(DOI reviewer) Check as completed	Standard	Reference (§ 44 refers to Neb. Rev. Stat. Chapter 44, Nebraska's Insurance Code)	Description	Applicant: Provide page number and specific reference to the contract provision
	/Pharmacy Participation Question 9(f)	Contracts		
	Maximum Allowable Cost (MAC) price list	§ 44-4608(1)(c)	Contract states how pharmacies can access the MAC list; must be in a readily accessible format that can be used by the contracted pharmacy.	
	MAC price list updated at least every seven business days	§ 44-4608(1)(a)	Contract includes commitment that MAC list will be updated at least every seven business days with changes in price from previous list specifically noted.	
	MAC price lookup	§ 44-4608(1)(a)	Contract states the means a pharmacy can use to review a current price in an electronic, print, or telephonic format within one business day of any such change at no cost to the pharmacy.	
	Prices not allowed on MAC list	§ 44-4608(2)	Contract includes statement that a drug will not be placed on the MAC list unless that drug is available for purchase by pharmacies in Nebraska from a national or regional drug wholesaler and is not obsolete.	

	Process to appeal,	§ 44-4608(3)	Contract must include a
	investigate, and	3	process to appeal,
	resolve disputes over		investigate, and resolve
	MAC prices		disputes regarding any MAC
	Winter prices		price.
	15 business day limit	§ 44-4608(3)(a)	PBM cannot appeal an initial
_	on right to appeal	3 44-4000(3)(a)	claim by a pharmacy after 15
	MAC price		business days (for appeals of
	WAC PILEC		MAC price).
	Seven business day	§ 44-4608(3)(b)	MAC price appeals must be
-	investigation and	<u>3 44-4008(3)(b)</u>	investigated and resolved
	resolution after		within 7 business days after
	appeal of MAC price		receipt by PBM.
		S 44 4C09(2\/s)	
	Reason for any MAC	§ 44-4608(3)(c)	Denial of a MAC price appeal must include a reason and
	price list appeal denial		
	and national drug		identify the national drug
	code		code for the drug that may
			be purchased by the
			pharmacy at a price at or
			below the price on the MAC
			price list as determined by
_		6.00.000(0)	the PBM.
	Valid MAC price	§ 44-4608(4)	Contract states that if a
	appeals one day price		pharmacy's MAC price
	adjustment and		appeal is successful, the
	pharmacy reverse and		price will be adjusted no
	rebill		later than one day after the
_			appeal is resolved.
	Gag clause	§ 44-4606(1)	Contract cannot prohibit or
	prohibitions		restrict disclosure, or
			penalize for disclosing:
			Nature of treatment, risks,
			and alternatives to
			treatment;
			Availability of an alternative
			therapy, consultation, or
			test;
			Decision of utilization
			reviewer to authorize or
			deny a service;
			The process used to
			authorize or deny a service
			or benefit;
			Information on any financial
			incentive or structure used
			by the health carrier.

Gag clause prohibitions	§ 44-4606(2)	Pharmacy is allowed to discuss information regarding total cost for a service for a drug; pharmacy is allowed to sell a more affordable alternative to the covered person if a more affordable alternative is available. Also see § 44-4606(5)(a), PBMs cannot require covered persons to pay more than the lesser of their cost sharing or the cash price.	
Gag clause prohibitions	§ 44-4606(3)	Contract cannot prohibit, restrict, or limit disclosure of information to the director, law enforcement, or government officials if: Recipient of information represents they have authority to maintain proprietary information as confidential; Prior to disclosure, the pharmacy marks documents containing proprietary information as confidential or requests confidential treatment for any oral communication of the information.	
Termination as a penalty for disclosing information	§ 44-4606(4)	Contract states that it cannot be terminated for disclosing information about a PBM practice unless: The pharmacist discloses trade secret information. Contract states that sharing any portion of the contract with the director is not grounds for termination.	
PBM audits of claims	§ 44-4607	Contract language related to the PBM's right to audit claims will be reviewed for compliance with the audit parameters set forth in §44-4607.	

	Writton appeals	8 44 4607(F)	Contract states the written
	Written appeals	§ 44-4607(5)	
	process and		appeal process which shall
	procedures for audits		include procedures for
			appealing both a preliminary
			audit report and a final audit
			report.
Complian			
• •	on Question 9(e)		
_			delines the PBM will use so that reviewers will
be able to	see that compliance has b	peen built into PBM operation	ons.
	Prescription drug	§ 44-4606(5)	Covered persons do not
1	payments by a	3 44 4000(3)	pay more than the lesser of
	covered person		
	covered person		cost sharing or cash price;
			payments are attributed
			toward deductible or
			MOOP.
	Maximum Allowable	§ 44-4608(1)(a) and (c)	Describes how the applicant
	Cost (MAC) price list		plans to provide timely
	updates in a usable		updates and maintain
	format		historical records.
	Procedure to	§ 44-4608(1)(b)	Describes how updates will
	eliminate a product		be made in a timely manner
	from the MAC price		to be consistent with any
	list		change in the marketplace.
	MAC price list drug	§ 44-4608(2)	Describes how purchase
	availability		availability will be
	,		documented.
	Pharmacy audit	§ 44-4607(1)	Includes a document that
	requirements		provides a detailed
	· .		description of the pharmacy
			audit process and includes
			all required provisions.
			The audit requirements of
			§ 44-4607 do not apply to
			investigative audits involving
			suspected fraud, willful
			misrepresentation, or abuse,
			or any audit completed by a
			state-funded health care
	Investigative audits	\$ 44 4607(0\	program. Describes how the auditing
_	Investigative audits	§ 44-4607(8)	Describes how the auditing
			entity will distinguish and
			document an investigative
			audit to investigate
			suspected fraud, willful
			misrepresentation, or abuse.

	1	
15 business day prior	§ 44-4607(1)(a)	Provides fifteen business
notice of onsite audits		days notice to any pharmacy
		prior to conducting an initial
		onsite audit.
Claims involving	§ 44-4607(1)(b)	Requires any audit that
clinical or professional		involves clinical or
judgment		professional judgment must
		be conducted by or in
		consultation with a
		pharmacist.
Audit standards and	§ 44-4607(1)(c)	Requires each pharmacy to
parameters		be audited under the same
		standards and parameters
		used for other similarly
		situated pharmacies.
Twenty-four month	§ 44-4607(2)(a)	Limits the audit period to
audit period		twenty-four months from
·		the date that the claim was
		submitted to the auditing
		entity unless a longer period
		is required under state or
		federal law.
Random sampling	§ 44-4607(2)(b)	Requires the auditing entity
method to determine		using random sampling as a
sample size		method for selecting a set of
		claims for examination to
		ensure the sample size is
		appropriate for a statistically
		reliable sample.
Masked list with	§ 44-4607(2)(c)	Provides the pharmacy a
prescription number		masked list containing any
or date range		prescription number or date
		range that the auditing
		entity is seeking to audit.
Onsite audit	§ 44-4607(2)(d)	Restricts onsite audit from
restriction during first	- 1111	taking place during the first
five business days of		five business days of the
the month		month without the consent
		of the pharmacy.

Onsite auditor restricted locations	§ 44-4607(2)(e)	Requires an auditor be escorted by a pharmacy employee in order to enter the area of any pharmacy where patient-specific information is available and, to the extent possible, each auditor is required to remain out of the sight and hearing range of any pharmacy customer.	
Statements or records allowed to validate a pharmacy record and delivery of a pharmacy service	§ 44-4607(4)	Permits the pharmacy to use an authentic and verifiable statement or record, including a medication administration record of a nursing home, assisted-living facility, hospital, physician, or other authorized practitioner or an additional audit documentation parameter located in the provider manual to validate a pharmacy record and the delivery of a pharmacy service. Any legal prescription including a medication administration record, fax, e-prescription, or documented telephone call from the prescriber to the prescriber's agent may be used to validate a claim in connection with a prescription, refill, or change in a prescription.	
Prohibition on requiring additional information written on a prescription	§ 44-4607(2)(g)	Provides that the PBM will not require information to be written on a prescription unless required by state or federal law.	
Interest accrual prohibited during audit period	§ 44-4607(3)(h)	Prohibits interest accrual during the audit period for either party, beginning with the notice of the audit and ending with the final audit report.	

Preliminary audit	§ 44-4607(6)(a)	Requires the preliminary
report delivery	<u>5 - 1 - 10 - 1 (0) (0) </u>	audit report to be delivered
, ,		to the pharmacy within one
		hundred twenty days after
		the conclusion of the audit.
Preliminary audit	§ 44-4607(5)	Includes the written appeal
report appeal process		process with procedures for
		appealing a preliminary
		audit.
Pharmacy allowed	§ 44-4607(6)(b)	Provides a pharmacy at least
thirty days to provide		thirty days following receipt
documentation to		of a preliminary audit report
address discrepancy in		to provide documentation to
preliminary audit		address any discrepancy
		found in the audit.
Final audit report	§ 44-4607(6)(c)	Requires the final audit
delivered within 120		report to be delivered to the
days after receipt of		pharmacy within one
preliminary audit or		hundred twenty days after
exhaustion of the		receipt of the preliminary
appeals process		audit report or the appeal
		process has been exhausted,
		whichever is later.
Final audit report	§ 44-4607(5)	Includes the written appeal
appeal process		process with procedures for
		appealing a final audit.
Remit money for	§ 44-4607(6)(d)	Requires an auditing entity
underpayments of a		to remit any money due to a
claim within 45 days		pharmacy or pharmacist as
		the result of an
		underpayment of a claim
		within forty-five days after
		the appeal process has been
		exhausted and the final audit
		report has been issued.

Recoupment for information not written on a prescription	§ 44-4607(2)(h)	Prohibits recoupment for information not written on a prescription unless the information is required in the provider manual or the information is required by the federal Food and Drug Administration or the drug manufacturer's product safety program and the information required is not readily available for the auditing entity at the time of the audit. No auditing entity or agent shall receive payment based on a percentage of any recoupment.	
Recoupment timing	§ 44-4607(2)(f)	Prohibits recoupment from being deducted from or applied against a future remittance until after the appeal process is complete and both parties receive the results of the final audit.	
Audit recoupment requirements	§ 44-4607(3)	Requires the pharmacy audit to meet all of the statutory criteria for recoupment listed below.	
Audit recoupment requirements	§ 44-4607(3)(a)	Includes consumer-oriented parameters based on manufacturer listings in the audit parameters.	
Compounded medication reimbursable cost methodology	§ 44-4607(3)(b)	Considers the pharmacy's usual and customary price for a compounded medication as the reimbursable cost unless the pricing method is outlined in the pharmacy provider contract.	

Projections prohibited to determine overpayment or underpayment	§ 44-4607(3)(c)	Overpayment or underpayment findings are based on the actual overpayment or underpayment and not a projection that relies on the number of patients served who have a similar diagnosis, the number of similar orders, or the number of refills for similar drugs.	
Extrapolation prohibited for recoupment or penalties	§ 44-4607(3)(d)	Audits cannot use extrapolation to calculate the recoupment or penalties unless required by state or federal law.	
Overpayments involving dispensing fees	§ 44-4607(3)(e)	Dispensing fees are not included in the calculation of an overpayment unless: A prescription was not actually dispensed; The prescriber denied authorization; The prescription dispensed was a medication error by the pharmacy; The identified overpayment is solely based on an extra dispensing fee.	
Record-keeping errors are not considered fraud	§ 44-4607(3)(f)	Provides any clerical or record-keeping error, such as a typographical error, scrivener's error, or computer error regarding a required document or record is not considered fraud. Such error may be subject to recoupment.	

When recoupment for errors is prohibited	§ 44-4607(3)(g)	Prohibits recoupment for an error resulting in no actual financial harm to the covered person or health benefit plan. An error that is the result of the pharmacy failing to comply with a formal corrective action plan may be subject to recoupment.	
Pharmacy audit reports and recoupments	§ 44-4607(7)	States whether an auditing entity is contractually required to provide a copy of the pharmacy audit to the plan sponsor for any of the plan sponsor's claims that were included in the audit and any recouped money must be returned to the health benefit plan or plan sponsor.	
Prohibits 340B Price Discrimination	§ 44-4609(1)	Provides for reimbursements of a 340B entity or a 340B contract pharmacy at the same rate paid for the same drug to similarly situated pharmacies that are not 340B entities or 340B contract pharmacies	
Prohibits assessing a fee, chargeback, or other adjustment upon 340B entities	§ 44-4609(1)	Does not assess any fee, chargeback, or other adjustment upon the 340B entity or 340B contract pharmacy on the basis that the 340B entity or 340B contract pharmacy participates in the program.	

Allows the consumer	§ 44-4609(2)	Does not discriminate	
the choice to use a		against a 340B entity or	
340B entity		340B contract pharmacy in	
		a manner that prevents or	
		interferes with a covered	
		individual's choice to	
		receive such drug from the	
		corresponding 340B entity	
		or 340B contract pharmacy	

CERTIFIC	ATION OF	COMP	PLIANCE
----------	----------	------	---------

I, the undersigned authorized filer, hereby certify that this application and related contracts comply with applicable Nebraska statutes to the best of my knowledge. This filing contains no prohibited content according to the statutes. I am authorized to sign on behalf of the Company identified below.	
Name of Company	
Typed Name of Authorized Applicant (Electronic Signature)	 Date